吉非替尼治疗晚期肺腺癌临床疗效观察

目的：探讨吉非替尼治疗晚期肺腺癌的临床疗效。方法随机选择2009年～2012年60例晚期肺腺癌患者，单药吉非替尼口服，250 mg/d，1次/天，疗程1年。用药后4周、8周、12周、24周、48周进行疗效评价和症状评定。结果吉非替尼治疗晚期肺腺癌有效率、总的疾病控制率、症状改善方面：①在治疗后直至12周为递增趋势，12～48周为递减趋势，两者比较，差异具统计学意义（P＜0.05）。②用药后4周、12周、24周、48周，女性疗效明显优于男性，两者间比较，差异具统计学意义（P＜0.05）。结论单用吉非替尼可以作为晚期肺腺癌患者的有效疗法，对晚期肺腺癌女性患者疗效明显优于男性患者。

The clinical curative effect of gefitinib in treating patients with end-stage lung adenocarcinoma

Objective to study the clinical curative effect of gefitinib in treating patients with end-stage lung adenocarcinoma .Methods 60 cases patients with end-stage Lung adenocarcinoma elected by a random methods were treated only with gefitinib（IRESSA）.The usage was gefitinib 250 mg each time, po, one time each day, all together to one year. To evaluate the therapeutic effect and the remission after 4 week、8 week、12 week、24 week、48 week treatment.Results For the effective rate, total disease control rateand remission of patients with end-stage Lung adenocarcinoma treated with gefitinib （IRESSA）： the trend was increase from first day to 12 week of the treatment period and decline from 12 week to 48 week of the treatment period. The difference between them was significant（P〈0.05）. For clinical curative effect of patients with end-stage Lung adenocarcinoma treated with gefitinib（IRESSA） in 4week, 12week,24week, 48week of the treatment period, female was obvious outbalance male,The difference between them was significant（P〈0.05）. Conclusions It is efficacious treatment for patients with end-stage lung adenocarcinoma to treat only with gefitinib（IRESSA）. For the female patients with end-stage lung adenocarcinoma, It is more efficacious than the male patients.